Xencor (NASDAQ:XNCR) Shares Down 5.3% – Time to Sell?

Xencor, Inc. (NASDAQ:XNCR) shares fell 5.3% on Wednesday . The company traded as low as $11.33 and last traded at $11.20. 141,268 shares changed hands during trading, a decline of 75% from the average session volume of 571,206 shares. The stock had previously closed at $11.82.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. StockNews.com lowered shares of Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $20.00 to $30.00 in a report on Monday, December 2nd. Finally, Wells Fargo & Company cut their target price on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.38.

Xencor Price Performance

The company has a 50-day moving average of $15.72 and a 200-day moving average of $20.14. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The firm has a market capitalization of $811.02 million, a price-to-earnings ratio of -3.60 and a beta of 0.74.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The firm had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. As a group, research analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Hedge Funds Weigh In On Xencor

Large investors have recently added to or reduced their stakes in the company. Sterling Capital Management LLC boosted its position in shares of Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,040 shares during the period. GF Fund Management CO. LTD. bought a new stake in Xencor in the 4th quarter valued at approximately $34,000. GAMMA Investing LLC lifted its stake in Xencor by 31.0% in the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 508 shares in the last quarter. Quarry LP grew its stake in shares of Xencor by 111.4% during the 3rd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock worth $80,000 after acquiring an additional 2,108 shares in the last quarter. Finally, KBC Group NV raised its holdings in shares of Xencor by 26.0% in the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 813 shares during the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.